Difficulty: Medium
Average Score: 82%
Practice
Chronic long-term therapy of myasthenia is usually accomplished with:
Correct answer
B
Rationale
In the treatment of myasthenia gravis, chronic long-term therapy is typically achieved with neostigmine (Option B). Neostigmine is a cholinesterase inhibitor that helps improve muscle strength by increasing the levels of acetylcholine at the neuromuscular junction. This pharmacological action is crucial in managing the symptoms of myasthenia gravis, a condition characterized by muscle weakness and fatigue due to autoimmune-mediated destruction of acetylcholine receptors.
Option A, edrophonium, is a short-acting cholinesterase inhibitor used for diagnostic purposes in myasthenia gravis to differentiate between myasthenic and cholinergic crises. It is not suitable for chronic therapy due to its short duration of action.
Option C, echothiophate, is a long-acting irreversible cholinesterase inhibitor primarily used in the treatment of glaucoma. It is not indicated for myasthenia gravis.
Option D, carbachol, is a non-selective cholinergic agonist mainly used in ophthalmology for conditions like glaucoma and intraocular pressure reduction. It is not a common choice for myasthenia gravis therapy.
Understanding the appropriate pharmacological agents for specific conditions like myasthenia gravis is vital for healthcare professionals, especially in the context of the NCLEX exam where clinical decision-making skills are tested. Neostigmine's mechanism of action and suitability for chronic therapy make it the correct choice in managing myasthenia gravis effectively over the long term.
Option A, edrophonium, is a short-acting cholinesterase inhibitor used for diagnostic purposes in myasthenia gravis to differentiate between myasthenic and cholinergic crises. It is not suitable for chronic therapy due to its short duration of action.
Option C, echothiophate, is a long-acting irreversible cholinesterase inhibitor primarily used in the treatment of glaucoma. It is not indicated for myasthenia gravis.
Option D, carbachol, is a non-selective cholinergic agonist mainly used in ophthalmology for conditions like glaucoma and intraocular pressure reduction. It is not a common choice for myasthenia gravis therapy.
Understanding the appropriate pharmacological agents for specific conditions like myasthenia gravis is vital for healthcare professionals, especially in the context of the NCLEX exam where clinical decision-making skills are tested. Neostigmine's mechanism of action and suitability for chronic therapy make it the correct choice in managing myasthenia gravis effectively over the long term.